Cempra's solithromycin meets gonorrhea endpoint

Cempra Inc. (NASDAQ:CEMP) said solithromycin met the primary endpoint in a Phase II to treat uncomplicated urogenital gonorrhea infection. All 22 evaluable patients achieved successful bacterial eradication at day seven after a single oral dose of the fluoroketolide/macrolide antibiotic. Successful eradication was measured by conversion from positive baseline urethral or cervical cultures to negative. Additional data are slated to be presented at a future medical meeting. Cempra said it plans to start a Phase III trial of oral solithromycin to treat uncomplicated urogenital gonorrhea infection after it secures funding. ...